13Q DELETIONS IN LYMPHOID MALIGNANCIES

M HERMANSON, D GRANDER, M MERUP, XS WU, M HEYMAN, O RASOOL, G JULIUSSON, G GAHRTON, R DETLOFSSON, N NIKIFOROVA, C BUYS, S SODERHALL, N YANKOVSKY, E ZABAROVSKY, S EINHORN

    Research output: Contribution to journalArticleAcademicpeer-review

    119 Citations (Scopus)

    Abstract

    Previous studies have indicated that a candidate tumor suppressor gene resides telomeric of the RB1 gene at 13q14, a region that is commonly deleted in B-cell chronic lymphocytic leukemia (B-CLL). In this study, we have evaluated the frequency and minimal region of overlap for 13q deletions in malignant cells from various lymphoid neoplasms. We observed losses at 13q14 in 33/75 (44%) B-CLL cases, four of 16 (25%) non-Hodgkin's lymphoma (NHL) cases, eight of 29 (28%) patients with acute lymphocytic leukemia (ALL), and one of 15 T-cell lines. In some ALL cases, inactivation of the RB1 gene is suggested as the important event in the 13q deletions. The most commonly deleted marker in CLL and NHL was D13S319, between RBkpt and the D13S25 loci. Homozygous deletions of this marker were observed in 10 of 75 B-CLL cases, in six of which the homozygous deletions included only the D13S319 locus. Our data suggest that 13q deletions are common in lymphoid neoplasms, and that deletion of a candidate tumor suppressor gene(s) in the vicinity of the D13S319 marker is a tumorigenic event in these diseases. (C) 1995 by The American Society of Hematology.

    Original languageEnglish
    Pages (from-to)1911-1915
    Number of pages5
    JournalBlood
    Volume86
    Issue number5
    Publication statusPublished - 1-Sep-1995

    Keywords

    • CHRONIC LYMPHOCYTIC-LEUKEMIA
    • RETINOBLASTOMA GENE
    • LOCUS
    • ABNORMALITIES
    • CELLS

    Cite this